Fresh analysis indicates that individuals who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end traditional diet and exercise regimens.
Research printed in a leading health publication points out that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"Users purchasing such medications should be cognizant of the risk of rapid rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb.
Such speed of recovery implies a reversion to pre-treatment weight in about 18 months.
Comparing Approaches
The analysis, which reviewed 37 of trials involving over 9,000 of patients, compared the outcomes of these new drugs with older methods.
The team emphasize that people who shed pounds through diet and exercise usually see a slower creep back—around 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Doctors suggest the mechanism of the drugs explains the accelerated rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates appetite.
"Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making excessive eating a significant risk."
A Lifelong Disease?
Medical guidelines recommend the jabs for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals say that, due to the high risk of relapse, the treatment is often ongoing.
This view is echoed by drug manufacturers, who state that the results "emphasize the chronic nature of excess weight," akin to managing diseases like hypertension.
Patient Accounts
Users who have stopped the medication explain a sudden return of cravings.
"I experienced a switch flipping and I was suddenly starving," recalled a patient.
This challenge is compounded if individuals have not developed lasting dietary or behavioural modifications during treatment.
Growing Use
Recent estimates indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with interest being substantial.
- Adoption is more common among females than males.
- The 40s and 50s age group shows the highest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, experts caution that while these medications are effective tools for shedding pounds, they are not a permanent solution and lasting health benefits hinges on ongoing lifestyle management.
